Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EOG Resources Inc (EOG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

EOG Resources IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

EOG Resources Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? EOG Resources Inc trades at $143.3 (market cap $75.22B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and EOG Resources Inc pays a 2.85% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

EOGVRTX
Market Cap
$75.22B$134.25B
Sector
EnergyHealth
52-Week High
$149.89$529.65
52-Week Low
$101.78$376.62
Enterprise Value
$78.56B$128.37B
Dividend Yield
2.85%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EOG Resources Inc

EOG Resources trades at $142.22, up 5.55% today, with strong earnings beats in recent quarters and a bullish technical signal. The stock shows robust profitability with a 25.81% net income margin and attractive valuation metrics, including a P/E of 11.16. Recent news highlights operational strength and institutional buying interest, supporting positive momentum.

The outlook remains favorable with a consensus price target of $157.88, indicating potential upside. Key risks include oil price volatility and capital expenditure intensity, but disciplined cost controls and shareholder returns provide stability. The stock presents a compelling opportunity for growth-oriented investors seeking energy exposure.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.

Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About EOG Resources Inc

EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.

Read more on EOG

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX